Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureCharlotte Martin, Edith Oyen, Yannick Van Wanseele, Tanila Ben Haddou, Helmut Schmidhammer, Jessica Andrade, Lynne Waddington, Ann Van Eeckhaut, Bruno Van Mele, James Gardiner, Annemieke Madder, Mariana Spetea, Steven Ballet
Abstract
Authors
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Comments and suggestions from pain specialists regarding the CDC's proposed opioid guidelines
10.1111/papr.12475 · 2016
Opiate pharmacology and relief of pain
10.1200/jco.2013.53.1079 · 2014
Pharmacogenetics of chronic pain management
10.1016/j.clinbiochem.2014.05.065 · 2014
Steady-state pharmacokinetic comparison of a new, extended-release, once-daily morphine formulation, Avinza™, and a twice-daily controlled-release morphine formulation in patients with chronic moderate-to-severe pain
10.1016/s0885-3924(02)00382-2 · 2002
Opioid guidelines in the management of chronic non-cancer pain
2006
The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health pathways to prevention workshop
10.7326/m14-2559 · 2015
Long-acting opioids for chronic pain: pharmacotherapeutic opportunities to enhance compliance, quality of life, and analgesia
10.1097/00045391-200105000-00006 · 2001
Extended-release opioids for the management of chronic non-malignant pain
10.1517/17425247.3.4.489 · 2006
Extended-release and long-acting opioids for chronic pain management
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
unpaywall
Confidence 95%
datacite
Confidence 0%
2014
Benefits of extended-release opioid analgesic formulations in the treatment of chronic pain
10.1111/j.1533-2500.2008.00232.x · 2009
Controlled-release of opioids for improved pain management
10.1016/j.mattod.2016.01.016 · 2016
The transdermal delivery of fentanyl
10.1016/j.ejpb.2013.01.018 · 2013
Injectable peptide hydrogels for controlled-release of opioids
10.1039/c5md00440c · 2016
Peptide-and protein-based hydrogels
10.1021/cm202640w · 2012
Hydrogels for protein delivery
10.1021/cr200157d · 2012
Self-assembled peptide-based nanostructures: smart nanomaterials toward targeted drug delivery
10.1016/j.nantod.2016.02.004 · 2016
Peptide- and protein-based hydrogels
10.1021/cm202640w · 2011
Cytocompatibility of self-assembled β-hairpin peptide hydrogel surfaces
10.1016/j.biomaterials.2005.01.029 · 2005
Assembly of an injectable noncytotoxic peptide-based hydrogelator for sustained release of drugs
10.1021/la4043638 · 2014
Self-Assembling peptide nanofibrous hydrogel as a versatile drug delivery platform
10.2174/1381612821666150901104821 · 2015
Peptide hydrogels
2013
Shear-thinning hydrogels for biomedical applications
10.1039/c1sm06513k · 2012
Stimuli responsive self-assembled hydrogel of a low molecular weight free dipeptide with potential for tunable drug delivery
10.1021/bm800404z · 2008
Self-assembling peptide nanofiber scaffolds for controlled release governed by gelator design and guest size
10.1016/j.jconrel.2010.08.002 · 2010
The effect of protein structure on their controlled release from an injectable peptide hydrogel
10.1016/j.biomaterials.2010.08.047 · 2010
Slow release of molecules in self-assembling peptide nanofiber scaffold
10.1016/j.jconrel.2006.06.031 · 2006
Unresolved referenced work
2000
Variation of the net charge, lipophilicity, and side chain flexibility in Dmt1-DALDA: effect on opioid activity and biodistribution
10.1021/jm3008079 · 2012
Chirality effects at each amino acid position on tripeptide self-assembly into hydrogel biomaterials
10.1039/c3nr06752a · 2014
Peptide based hydrogels for cancer drug release: modulation of stiffness, drug release and proteolytic stability of hydrogels by incorporating d-amino acid residue (s)
10.1039/c6cc01744d · 2016
Structural dynamic of a self-assembling peptide d-EAK16 made of only D-amino acids
10.1371/journal.pone.0002364 · 2008
The unexpected advantages of using D-amino acids for peptide self-assembly into nanostructured hydrogels for medicine
10.2174/1568026616999160212120302 · 2016
Supramolecular hydrogel of a d-amino acid dipeptide for controlled drug release in vivo
10.1021/la804271d · 2009
Peptidomimetics, a synthetic tool of drug discovery
10.1016/j.cbpa.2008.03.009 · 2008
On the concept of linear modified retro-peptide structures
10.1021/ar50133a001 · 1979
The design, synthesis and application of stereochemical and directional peptide isomers: a critical review
10.2174/1389203033487054 · 2003
Mixed alpha-beta peptides as a class of short amphipathic peptide hydrogelators with enhanced proteolytic stability
10.1021/acs.biomac.5b01319 · 2016
Rheological properties of peptide-based hydrogels for biomedical and other applications
10.1039/b919449p · 2010
Stopping of crosslinking reaction in a PDMS polymer at the gel point
10.1007/bf00263470 · 1985
Evolution-based design of an injectable hydrogel
10.1002/adfm.201102330 · 2012
10.1124/jpet.105.096032
10.1124/jpet.105.096032 · doi-reference
Synthesis and Biological Evaluation of 14-Alkoxymorphinans. Part 8. 14-methoxymetopon, an extremely potent opioid agonist
10.1002/hlca.19900730623 · doi-reference
14-Methoxymetopon, a very potent μ-opioid receptor-selective analgesic with an unusual pharmacological profile
10.1016/s0014-2999(02)02821-2 · doi-reference
14-Methoxymetopon, a potent opioid, induces no respiratory depression, less sedation, and less bradycardia than sufentanil in the dog
10.1097/00000539-200006000-00018 · doi-reference
Highly potent novel opioid receptor agonist in the 14-alkoxymetopon series
10.1016/0014-2999(93)90591-5 · doi-reference